Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Genticel HPV Vaccine Study on Track

July 11, 2014 11:19 am | News | Comments

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announce that the enrollment of the Phase 2 RHEIA-VAC study has reached the halfway mark of its recruitment target, and the study is on track with Genticel’s initial projections. Read more...

TOPICS:

Sigma-Tau Submits EMA Application for ALL Drug

July 11, 2014 11:13 am | News | Comments

Sigma Tau Rare Disease announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. Read more...

TOPICS:

HD Biosciences, Marshall University Partner on Drug Discovery

July 11, 2014 11:08 am | News | Comments

HD Biosciences Co. Ltd., the Marshall Institute for Interdisciplinary Research and the Marshall University Joan C. Edwards School of Medicine announced the new partnership to co-develop potential anti-cancer drugs to provide innovative medicines for unmet healthcare needs and targets. Read more...

TOPICS:
Advertisement

Scientists Advance Search for Novel Materials

July 11, 2014 11:00 am | News | Comments

Scientists at Stanford University and the Department of Energy’s SLAC National Accelerator Laboratory have found a way to estimate uncertainties in computer calculations that are widely used to speed the search for new materials for industry, electronics, energy, drug design and a host of other applications. Read more...

TOPICS:

Addressing Side Effects of Mainstream Treatments

July 11, 2014 10:52 am | by Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus Therapeutics Inc. | Articles | Comments

The highest-profile symptoms of major diseases are well publicized, yet for many, the side effects of mainstream therapies for these diseases can also impact physical and psychological well-being. Luckily, advances in drug delivery have offered novel treatments. Read more...

TOPICS:

JDRF, Lexicon Collaborate on Phase 2 Diabetes Trial

July 10, 2014 12:00 pm | News | Comments

Lexicon Pharmaceuticals announced that JDRF will provide funding to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in a younger population with T1D. Read more...   

TOPICS:

Vaccine Achieves Simultaneous Protection Against Ricin, Anthrax

July 10, 2014 12:00 pm | News | Comments

Soligenix Inc. announced that the combination of RiVax and VeloThrax induces protective immunity to both ricin toxin and anthrax toxin exposure. Read more...                           

TOPICS:

Tiny DNA Pyramids Enter Bacteria, Deliver Deadly Payload

July 10, 2014 12:00 pm | News | Comments

Bacterial infections usually announce themselves with pain and fever but often can be defeated with antibiotics— and then there are those that are sneaky and hard to beat. Now, scientists have built a new weapon against such pathogens in the form of tiny DNA pyramids. Read more...

TOPICS:
Advertisement

NIH Launches Phase 1 Trial of Novel C. Diff Drug

July 10, 2014 12:00 pm | News | Comments

The National Institute of Allergy and Infectious Diseases has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. Read more...     

TOPICS:

Astellas Submits NDA for Life-Threatening Fungal Infection Drug

July 10, 2014 12:00 pm | News | Comments

Astellas announced it has submitted a New Drug Application to the FDA seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis. Read more...                 

TOPICS:

Review: Gaps Between Approval, Safety Assessment of ADHD Drugs

July 10, 2014 12:00 pm | News | Comments

Over the last 60 years, the FDA approved 20 medications for ADHD based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers report. Read more...        

TOPICS:

PerkinElmer Launches LabChip GX and GXII Touch

July 9, 2014 3:32 pm | Product Releases | Comments

PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, announced the launch of the new LabChip GX Touch and GXII Touch automated electrophoresis systems. Read more...

Ario Kicks Off Efficacy Trial of Chronic Idiopathic Cough Drug

July 9, 2014 3:14 pm | News | Comments

Ario Pharma Ltd, the biopharmaceutical company developing innovative new treatments for respiratory disease, announced that it has commenced a Phase 2a study of its oral TRPV1 antagonist, XEN-D0501, for the treatment and prevention of cough in patients with chronic idiopathic cough. Read more...

TOPICS:

DelMar Receives Canadian Funding

July 9, 2014 3:09 pm | News | Comments

DelMar Pharmaceuticals Inc. announced that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP) to support personnel and research costs. Read more...

TOPICS:

Dezima Extends Clinical Development of Dyslipidemia Drug

July 9, 2014 3:02 pm | News | Comments

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced the approval of a Phase 1 pilot study in subjects with isolated, elevated Lipoprotein(a) (Lp(a)), for which additional funding has been secured. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading